UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000052253
Receipt number R000059328
Scientific Title A dose-ranging study to evaluate the effects of probiotics-containing foods on improving bowel movement -a randomized double-blind placebo-controlled study-
Date of disclosure of the study information 2023/10/30
Last modified on 2024/09/20 10:44:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A dose-ranging study to evaluate the effects of probiotics-containing foods on improving bowel movement -a randomized double-blind placebo-controlled study-

Acronym

A dose-ranging study to evaluate the effects of probiotics-containing foods on improving bowel movement -a randomized double-blind placebo-controlled study-

Scientific Title

A dose-ranging study to evaluate the effects of probiotics-containing foods on improving bowel movement -a randomized double-blind placebo-controlled study-

Scientific Title:Acronym

A dose-ranging study to evaluate the effects of probiotics-containing foods on improving bowel movement -a randomized double-blind placebo-controlled study-

Region

Japan


Condition

Condition

Healthy volunteers

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the effects of probiotics-containing foods on improving bowel movement

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Defecation frequency

Key secondary outcomes

Defecation time, Stool volume, Bristol stool scale, Stool color, Stool odor, Refreshing feeling after defecation, Feeling of rectal fullness, Straining during defecation, Ease of defecation, Pain during defecation, Good feeling after defecation, Painful urge to defecate, Satisfaction with defecation, Feeling of stool accumulation in the abdomen , Abdominal discomfort, Abdominal distention or bloating, Feeling of heaviness in the abdomen, Feeling of refreshment in the abdomen, Flatus frequency


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

5

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake of test food 1 for 2 weeks

Interventions/Control_2

Intake of test food 2 for 2 weeks

Interventions/Control_3

Intake of test food 3 for 2 weeks

Interventions/Control_4

Intake of test food 4 for 2 weeks

Interventions/Control_5

Intake of placebo for 2 weeks

Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1) Subjects whose age is 20 years or more and less than 65 years
2) Subjects whose defecation frequency is between 3 and 5 times per week
3) Subjects whose average of Bristol stool scale for a week is 3 or less
4) Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the study and being able to personally sign a written informed consent

Key exclusion criteria

1) Subjects who meet the diagnostic criteria for chronic constipation according to chronic constipation medical treatment guidelines 2017
2) Subjects receiving a medical treatment for serious hepatic, cardio-vascular, respiratory, endocrine or metabolic disorders
3) Subjects who have the possibility of developing allergic symptoms by the test food
4) Subjects who take Foods for Specified Health Uses or Foods with Function Claims labeled the intestine function
5) Subjects who take a large amount of foods which would affect the intestine function
6) Female subjects who are pregnant or lactating, or intending to become pregnant during the study
7) Subjects who have collected more than 200 mL of blood within 1 month or more than 400 mL within 3 months prior to the start of the present study (e.g. donated blood)
8) Subjects who took part in another clinical study within 3 months prior to the start of the present study or who are currently taking part in another clinical study
9) Subjects deemed unsuitable by the investigator

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Mamiko
Middle name
Last name Kohno

Organization

Morishita Jintan Co., Ltd.

Division name

Product Research Group, Research and Development Department, Business Management Headquarters

Zip code

573-0128

Address

2-11-1, Tsudayamate, Hirakata-shi, Osaka

TEL

072-800-1044

Email

m_kohno@jintan.co.jp


Public contact

Name of contact person

1st name Tomohiro
Middle name
Last name Sugino

Organization

Soiken Inc.

Division name

R&D Division

Zip code

560-0082

Address

Senri Life Science Center 13F, 1-4-2, Shinsenri-higashimachi, Toyonaka-shi, Osaka

TEL

0668718888

Homepage URL


Email

sugino@soiken.com


Sponsor or person

Institute

Morishita Jintan Co., Ltd.

Institute

Department

Personal name

Tomohiro Sugino


Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB of Fukuda Clinic

Address

Shin-Osaka brick building 2F, 1-6- 1 Miyahara, Yodogawa-ku, Osaka-shi, Osaka

Tel

06-6398-0203

Email

fukudaclinicIRB@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 10 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2023 Year 07 Month 15 Day

Date of IRB

2023 Year 07 Month 15 Day

Anticipated trial start date

2023 Year 10 Month 31 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 09 Month 20 Day

Last modified on

2024 Year 09 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059328